Clinical Trial Update: Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. [Phase 2]

View source ↗

Summary

Genfit completed a Phase 2 pilot trial investigating GFT505 (80 mg) in patients with impaired glucose tolerance and abdominal obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominal Obesity
• Impaired Glucose Tolerance

Drugs mentioned

• GFT505

Snippet

Sponsor: Genfit | Conditions: Impaired Glucose Tolerance, Abdominal Obesity | Phase 2 | Status: COMPLETED